




















A Polypill strategy at the Heart of cardiovascular secondary prevention 
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Over recent decades, cardiovascular disease (CVD) has overtaken infectious diseases as the leading cause of 
death worldwide.[1] This shift is partly due to the great advances in the treatment of infectious diseases and 
the success of associated public health campaigns. General public awareness of the importance both of 
preventing high-risk exposure and of early therapy initiation and adherence has helped reduce the burden of 
communicable (infectious) diseases. This contrasts sharply with the story of non-communicable diseases such 
as CVD. The incidence of atherosclerosis (the single largest underlying cause of CVD) has increased 
exponentially due to the immense lifestyle changes witnessed first in developed countries but lately also in 
low- and middle-income countries. This rapid worldwide change in lifestyle has resulted in dramatic increases 
of obesity, sedentarism, dyslipidemia, and hypertension, all of which are risk factors for atherosclerosis;  
The control of modifiable cardiovascular risk factors, such as lipid levels, blood pressure, etc., has a clear 
impact in reducing the likelihood of experiencing a cardiovascular event, and this holds true for both primary 
and secondary prevention. The leading cardiovascular scientific societies dedicate major efforts to providing 
guidelines to enable clinicians to define specific targets for each of these modifiable factors based on a 
patient’s risk profile. The most recent European Society of Cardiology (ESC) “Guidelines on cardiovascular 
disease prevention in clinical practice”, released in 2016, established low density lipoprotein (LDL)-
cholesterol targets of 70, 100, and 115 mg/dL for individuals at very high, high, and low-to-moderate risk, 
respectively, and a blood pressure target of <140/90 mmHg (140/85 mmHg for most patients with diabetes).[2] 
The identification of risk factors allows gross prediction of future cardiovascular events such as myocardial 
infarction (MI), stroke, etc.  
Patients experiencing an acute cardiovascular event today have a high likelihood of surviving the episode 
thanks to the great therapeutic advances in MI and other acute conditions. However, these patients remain at 
high risk of subsequent events, with long-term consequences for the affected individuals (disability, 
absenteeism, etc.) and for health care budgets. Clinical research over recent decades has identified several 
pharmacological routes to effectively reducing the incidence of adverse events in survivors of MI and other 
acute conditions. These therapeutic options all receive clinical practice guideline recommendations for 
specific conditions.[3, 4] Task forces commissioned to prepare these documents review available data about 
the efficacy of specific therapies. In devising these recommendations, the greatest weight is given to evidence 
from adequately powered randomized clinical trials. However, it is important to bear in mind that patients 
enrolled in clinical trials are monitored closely, and medication adherence is therefore usually high. In real 
life treatment adherence is significantly lower than in controlled trials, with the result that the real-life efficacy 
of prescription drugs is lower than anticipated. Data from European cohort studies found that up to 9% of all 
CVD events can be attributed to poor adherence to cardiovascular medications.[5] In a recent analysis of 
≈4000 post-MI patients, patients fully adhering to medication (taking prescribed drugs >80% of days) had a 
significantly lower incidence of major adverse cardiovascular events (MACE) than those with partial 
adherence (40-80% of days covered) or non-adherence (<40%) (MACE incidence 19%, 25%, and 26%, 
respectively).[6] In addition, full treatment adherence results in lower per-patient annual direct medical costs 
for MI hospitalization than partial or non-adherence.[6] One major reason for non-adherence to secondary 
prevention medication is the complexity of treatment, which usually involves a high number of daily 
prescribed pills.[7] This problem is by no means specific to CVD, but affects many other conditions requiring 
treatment combinations. The introduction of a polypill strategy for patients with infectious diseases 
(tuberculosis, HIV, etc.) has successfully facilitated access and adherence to medication, and has even reduced 
associated distribution costs.[8] These polypills have become the mainstay therapy for most patients with these 
infectious diseases. Atherosclerosis seems a perfect scenario for the adoption of a polypill strategy, since 
clinical practice guidelines recommend a high number of medications after an acute event.[3, 4] Unexpectedly, 
although one secondary prevention cardiovascular polypill containing aspirin, ramipril, and atorvastatin 
received approval from the European Medicines Agency (EMA) in 2014,[9] this strategy has not been 
universally adopted. 
In the present issue of the journal, Selak and colleagues[10] present an individual participant data meta-





antihypertensive drug) with standard care. The main goal of the analysis was to determine the proportion of 
patients in the polypill and usual care arms meeting 2016 ESC prevention guideline[2] targets for LDL-
cholesterol, blood pressure, and antiplatelet use. The analysis included 3140 patients with a prior CVD event 
(secondary prevention) or who were at high risk of their first event (primary prevention). The trials included 
in the meta-analysis were IMPACT (n≈500 patients), Kanyini-GAP (n≈600), and UMPIRE (n≈2,000). The 
three trials were conducted between 2010 and 2013 as part of the pre-established SPACE (Single Pill to Avert 
Cardiovascular Events) collaboration. The three trials thus followed the same protocol, with only minor 
regional adaptations.[11] The SPACE consortium already published the results of an individual participant 
data meta-analysis of these trials,[12] showing that the polypill strategy significantly improved medication 
adherence, resulting in a significant improvement in systolic blood pressure and LDL-cholesterol levels 
compared with usual care.[12] In the present study, Selak and colleagues used the same database to determine 
if these improvements resulted in a higher proportion of patients meeting the targets set by the ESC prevention 
guidelines.[2] The main finding of the present study is that a higher proportion of patients in the polypill arm 
achieved the recommended targets for LDL-cholesterol (39% in polypill vs 34% in usual care) and blood 
pressure (62% vs 58%). Adherence to antiplatelet therapy (only applicable to secondary prevention patients) 
did not differ (96% in both arms). The proportion of patients meeting the three targets simultaneously was 
significantly higher in patients included in the polypill arm than in those in the usual care arm (24% vs. 19%). 
Despite being a not pre-specified analysis, these results are very important and provide significant incremental 
information to their previous meta-analysis.[12] One limitation of this analysis is that it only presents data 
collected in the SPACE collaboration trials, which were conducted 5-8 years ago. Relevant data from more 
recent trials, like the FOCUS (Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention) 
trial[13] were not included. In the European Union FP7-funded FOCUS trial, ≈700 post-MI patients were 
randomized to a polypill strategy (aspirin, statin and ramipril) or to usual care. Adherence to medication was 
significantly higher in the polypill strategy group (51% vs 41% in usual care group).[13] After completion of 
the FOCUS trial, the cardiovascular “Fuster polypill”—containing aspirin, ramipril, and a statin—received 
approval for clinical use in 2014 and is currently available in more than 30 countries.[9] 
As the Salek study confirms, the evidence supporting the benefits of a cardiovascular polypill strategy in high 
risk patients is compelling. Given that this strategy results in higher treatment adherence and better control of 
modifiable risk factors, the 2016 ESC cardiovascular prevention guidelines included for the first time a 
recommendation for its use.[2] A year later, the 2017 ESC guidelines for the treatment of patients with ST-
segment elevation myocardial infarction[4] included the same recommendation, in line with the prevention 
guidelines. In these two major ESC guideline documents, the class of recommendation for the cardiovascular 
polypill is set at IIb, with a level of evidence B. Given the consistent benefits across trials, one might question 
why the class of recommendation for this strategy is not stronger. The main reason is the lack of direct data 
showing that the increased adherence and better control of risk factors associated with the use of the 
cardiovascular polypill result in significant reductions in hard endpoints. To date no trial has had the power to 
test this hypothesis. To address this need, the European commission (H2020)-funded SECURE (Secondary 
Prevention of Cardiovascular Disease in the Elderly) trial is being conducted under the coordination of the 
Spanish National Center for Cardiovascular Research (CNIC) in Spain (ClinicalTrials.gov Identifier: 
NCT02596126). The ongoing SECURE trial will randomize 3200 post-MI patients in 7 European countries 
(Spain, Italy, Czech Republic, Germany, France, Poland, and Hungary) to receive the “Fuster Polypill” 
(aspirin, ramipril, and atorvastatin) or to usual care (the 3 medications separately). This study is powered to 
identify differences in MACE (cardiovascular death, nonfatal MI, nonfatal ischemic stroke, and urgent 
revascularization) over a minimum 2-year follow-up. The bad news is that results of this trial will not be 
available before 2022.  
In summary, there is robust evidence that the use of a cardiovascular polypill strategy results in increased 
adherence to treatments, to better control of modifiable risk factors, and to a higher proportion of patients 
meeting ESC guideline targets for LDL-cholesterol and blood pressure. Although there is still no data showing 
that these benefits translate into a reduction in hard endpoints, adoption of this strategy can now be considered 
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